Navigation Links
British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer

Study Shows 51% Reduction in Intestinal Adenomas Suggesting Possible Beneficial Mediation in the Prevention of Intestinal Cancer

EL DORADO HILLS, Calif., March 07, 2007 /PRNewswire/ -- NutraCea announced today the results of a study on the effect of rice bran on the number of intestinal adenomas in cancerous mice, published in the January 9, 2007 online edition of the prestigious British Journal of Cancer conducted at the Department of Cancer Studies and Molecular Medicine, at the University of Leicester, Leicester, UK, has produced some encouraging results on the dietary benefits of rice bran. The results of the controlled study demonstrated that by consuming a suitable daily dose of stabilized rice bran, an average 51% reduction in the number of precancerous adenomas in the stomach and large intestine of mice was observed.

"The results show that the mice that received stabilized rice bran (30%) into their diets had a significant decrease in the number of intestinal adenomas compared to mice on the control diet. Rice bran also decreased intestinal hemorrhage in this group," said Margie Adelman, Senior Vice President of NutraCea. "When rice bran in the mice diet was reduced from 30% to 10%, adenoma development was not significantly retarded compared to those in the control model. This suggests that adenoma-retarding activity of rice bran is dose-related, possibly linked predominately to the fiber content of the bran."

Prof. Andreas Gescher of the University of Leicester in the UK, the principal investigator, says: "We compared the cancer-preventive efficacy of NutraCea Stabilized Rice Bran in mouse models of prostate, breast and intestinal cancers. These mice ate a diet containing 30% rice bran. Whilst there was no effect of rice bran on the development of prostate or breast cancer, rice bran significantly retarded the development of adenomas in so-called "Min mice," a mouse strain which is prone to getting intestinal adenomas. The effect was dependent on the fiber content of the bran. The dose, which was efficacious in these mice translates into approximately 200g rice bran per day in humans. Some scientists believe that Min mice are a reasonable model of early stages of colorectal cancer in humans. Therefore, we feel that to study the potential colorectal cancer-preventing properties of stabilized rice bran in humans may be a promising idea."

The stabilized rice bran used in the study was NutraCea Stabilized Rice Bran Regular and NutraCea RiSolubles(R), both produced by NutraCea in the U.S. NutraCea's Chief Science Officer, Dr. Rani Madhavapeddi Patel comments, "This recent data validates what we have known about our stabilized rice bran for a long time; that the long-term health benefits have huge potential for the prevention of many of today's critical diseases. Obviously more research is needed, but for people at risk of colon cancer, daily consumption of our stabilized rice bran is a simple and safe way to take a pro-active, preventative approach."

"The fiber content in our stabilized rice bran is about 29%. However, with this study demonstrating that the active ingredient in the rice bran is the fiber, we are even more convinced that our Fiber Complex, which is the insoluble fraction of the rice bran and is comprised of 43% fiber, would produce even more significant results than the stabilized rice bran," Adelman added. "In fact, we don't know what further benefits the high antioxidant and rich phyto-nutrient profile might have added to the fiber's anti-cancer activity. However, we do concur with the researchers that the short chain fatty acids and butyrates formed in the colon from the breakdown of the rice bran are most likely the mechanism that makes the addition of stabilized rice bran to our daily diet a promising treatment for the prevention of colon cancer," said Adelman.

About NutraCea

NutraCea is a world leader in production and utilization of stabilized rice bran. They hold many patents for stabilized rice bran production technology and proprietary nutraceutical formulas ranging from arthritis, chronic bowel conditions, and effective diabetes control to cardiovascular disease treatment protocols. NutraCea's proprietary technology enables the creation of food and nutrition products to be unlocked from rice bran, normally a waste by-product of standard rice processing. Committed to helping the underfed, they're heavily involved in providing product and technology for developing countries through NutraCea's RiceAde feeding program. More information can be found in the Company's filings with the SEC and you can visit the NutraCea web site http://www.NutraCea.com.

Forward Looking Statements

This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the pending matters considered by the Company may not proceed as contemplated and the matters specified in the Company's filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward- looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company's filings with the Securities and Exchange Commission, including the company's most recent periodic report.

     Company Contact:

     Margie Adelman

     Senior V.P. NutraCea

     916-933-7000 Ext. 646

     916-220-3500 cell

     


     Media Contact:

     Tamara York, Director
 of Public Relations

     ADinfinitum

     212-693-2150, ext. 314

     


     Investor Relations Contact:

     Stephen D. Axelrod, CFA

     Wolfe Axelrod Weinberger Associates, LLC

     212-370-4500

     

madelman@nutracea.com tamara@adinfinitumny.com steve@wolfeaxelrod.com

CONTACT: Margie Adelman, Senior V.P. of NutraCea, +1-916-933-7000, ext.646, or mobile, +1-916-220-3500, or ; or media, TamaraYork, Director of Public Relations of ADinfinitum, +1-212-693-2150, ext.314, or ; or investors, Stephen D. Axelrod, CFA ofWolfe Axelrod Weinberger Associates, LLC, +1-212-370-4500, or, both for NutraCea madelman@nutracea.com tamara@adinfinitumny.com steve@wolfeaxelrod.com

Web site: http://www.nutracea.com/

Ticker Symbol: (NASDAQ-OTCBB:NTRZ),(NASDAQ-OTCBB:NTRZ)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
4. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
5. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
6. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
7. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
8. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
9. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
10. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
11. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 Global Surgical ... devices are tubes used to remove excess liquid and ... serum, pus, urine, bile or lymph. Surgical drains are ... surgery such as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic ... prophylactic post-surgery to prevent accumulation of fluid e.g. blood ...
(Date:4/19/2017)... 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and other unmet ... previously announced underwritten public offering of 23,625,084 shares ... price of $2.00 per share, before deducting underwriting ... by Sorrento.  The net proceeds to Sorrento from ...
(Date:4/19/2017)... OAKS, Calif. , April 19, 2017 /PRNewswire/ ... industrial buildings it is developing at Conejo Spectrum ... , to Atara Biotherapeutics, Inc. , ... with severe and life-threatening diseases that have been ... on allogeneic T-cell therapies for cancer, autoimmune and ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... Rod Burkett, CEO of Gardant Management Solutions, ... Rod has been at the forefront of Gardant since it was founded in 1999. ... overseen the opening of more than 40 new senior living communities. With his leadership, ...
(Date:4/24/2017)... ... 2017 , ... Donna Parker, L. Ac. reads all sorts of books on ... to be very practical. She wanted to write a guide/workbook that would give readers ... It prompted her in writing “ A Clear Path to a Vibrant Life : ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... will be attending the 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue Regeneration ... Reconstruction Foundation will present its annual Global Symposium at the Fontainebleau Hotel located ...
(Date:4/23/2017)... ... April 23, 2017 , ... "An event Horizon is a ... process rendered in my Art and Music. These are created as Metaphysical Transformations where ... boundary of mystery culminate to the ultimate singularity.", -- Karen Salicath Jamali , Karen ...
(Date:4/22/2017)... ... April 22, 2017 , ... Brian Emmer brings ... of Sales and Business Development at OAKWORKS, Inc. Mr. Emmer is responsible ... and strategic planning for the company. Recognized industry-wide as a healthcare innovator, ...
Breaking Medicine News(10 mins):